{"filings":[{"id":1417236,"accession_number":"0000950103-26-010195","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-07-02T21:07:26+00:00","items":["5.02"],"status":"ready","headline":"ADC Therapeutics grants $2.9M cash and 1.1M RSU retention awards to CEO, CFO, CMO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Ameet Mallik receives $1,795,500 cash and 675,000 RSUs; CFO Jose Carmona $541,842 cash and 203,700 RSUs; CMO Mohamed Zaki $568,974 cash and 213,900 RSUs.","Cash awards payable July 15, 2026; subject to repayment if employment ends before June 30, 2027 (exceptions for termination without cause or for good reason).","RSUs vest on June 30, 2027 or earlier upon termination without cause or for good reason, subject to continued employment.","Awards approved by Board with advice of independent compensation consultant on June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1232356,"accession_number":"0000950103-26-009416","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-06-24T13:00:38+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ADC Therapeutics cuts 17% of workforce, expects $10M annual savings; pre-sBLA meeting in Aug 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~17% globally, expected to generate ~$10M annualized cost savings.","One-time pre-tax charges of ~$3M for severance and termination costs, mostly in Q2 2026.","Pre-sBLA meeting with FDA in August 2026 for ZYNLONTA in r/r DLBCL; sBLA submission planned for Q4 2026.","LOTIS-7 trial data anticipated by end of 2026; cash runway at least into 2028.","Reorganization driven by completion of LOTIS-5 and LOTIS-7 trials and operational efficiencies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":834038,"accession_number":"0000950103-26-008465","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-06-03T20:17:06+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ADC Therapeutics: LOTIS-5 Phase 3 meets PFS endpoint; sBLA submission planned Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PFS HR=0.73 (p=0.008); median PFS 6.1 mo ZYNLONTA+ritux vs 4.7 mo R-GemOx.","ORR 58.1% vs 45.2%; CR 39.5% vs 26.7%; median DoCR 16.8 vs 12.3 mo.","Grade 5 TEAEs higher in test arm (13.2% vs 4.6%); majority in patients ≥75 years.","Plans pre-sBLA meeting with FDA in August; sBLA submission expected Q4 2026.","Company will evaluate value-maximizing alternatives, including cost reduction initiatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":805679,"accession_number":"0000950103-26-008321","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-06-02T20:01:37+00:00","items":["5.07","9.01"],"status":"ready","headline":"ADC Therapeutics shareholders approve capital range increase, equity plan expansion at 2026 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Approved increase in authorized shares under 2019 Equity Incentive Plan: 46.6M for, 18.9M against.","Capital range expanded to CHF 10.4M lower / CHF 15.6M upper limit.","Conditional share capital for financing increased from 38.0M to 48.0M shares.","Board compensation capped at $2.5M; executive fixed $2.6M + variable $5.5M.","All nine director nominees reelected; all 12 proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95341,"accession_number":"0001628280-26-029524","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics Q1 net product revenue $20.0M, net loss $0.21/share; cash runway into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $20.0M (up 15% YoY from $17.4M).","Net loss $33.0M ($0.21/share) vs $38.6M ($0.36/share) in Q1 2025; adjusted net loss $19.7M ($0.13/share).","Cash $231.0M as of Mar 31, 2026; cash runway at least into 2028.","LOTIS-5 Phase 3 topline results expected Q2 2026; full data and LOTIS-7 data by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":20851000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108313,"accession_number":"0001628280-26-016238","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics posts Q4 revenue $22.3M; net loss narrows; LOTIS-5 topline data expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product revenue $22.3M, full year $73.6M, up from $16.4M and $69.3M respectively in 2024.","Q4 net loss $6.4M ($0.04/share) vs $30.7M ($0.29/share) in 2024; adjusted net loss $13.5M.","Cash and cash equivalents $261.3M; expected cash runway at least into 2028.","LOTIS-5 Phase 3 topline data in 2L+ DLBCL expected Q2 2026; LOTIS-7 full data by year-end 2026.","Amendment to HealthCare Royalty financing reduces change-of-control payment to $150M through 2027; warrants for 9.8M shares at $3.81."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108312,"accession_number":"0000950103-26-002466","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ADC Therapeutics cuts change-of-control payment to HCR from $750M to $150-200M; issues warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Under amended HCR agreement, change-of-control payment reduced to $150M before 2028 or $200M after, from $750M previously.","Post-change-of-control royalties continue unless bought out for $525M-$750M less payments already made.","ADC issued warrants to HCR for 9,834,776 common shares at $3.8130 per share, exercisable until Dec 31, 2030.","Warrants are non-transferable before Jan 1, 2028; registration statement to be filed within 30 business days.","HCR had already provided $300M under original 2021 agreement; amendment reduces ADC's near-term buyout risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108311,"accession_number":"0000950103-26-000349","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADC Therapeutics posts updated corporate presentation with no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["ADC Therapeutics made available an updated corporate presentation dated January 2026 via 8-K filing.","The presentation excerpt contains only forward-looking statements boilerplate; no specific financial data or events.","No changes to guidance, pipeline status, or leadership were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108310,"accession_number":"0001628280-26-001386","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ADC Therapeutics reports preliminary 2025 revenue of ~$73M; cash runway extended to 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2025 ZYNLONTA net product revenue ~$22M; full year 2025 ~$73M vs $69.3M in 2024.","Cash and cash equivalents ~$261M as of Dec 31, 2025; expected cash runway at least to 2028.","LOTIS-7 Phase 1b shows 89.8% ORR and 77.6% CR; enrollment completion expected H1 2026.","LOTIS-5 Phase 3 topline data expected in Q2 2026; potential sBLA and approval mid-2027 if positive.","IND-enabling activities completed for PSMA-targeting ADC; partnership opportunities being explored."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124765,"accession_number":"0000950103-25-015818","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ADC Therapeutics reports 89.8% ORR and 77.6% CR in LOTIS-7 trial of ZYNLONTA + glofitamab in r/r DLBCL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Best ORR 89.8% (44/49); CR rate 77.6% (38/49) across dose levels.","At 150 µg/kg dose, ORR 85.7% and CR 75.0%.","In primary refractory patients (n=25): ORR 80%, CR 64%.","Of 8 prior CAR-T patients, 6 achieved CR.","Grade 3+ neutropenia (32.7%); manageable safety profile overall."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124764,"accession_number":"0001628280-25-050796","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics Q3 net product revenue $15.8M; net loss narrows to $41M; $60M PIPE strengthens cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product revenue $15.8M (down 12% YoY); nine-month 2025 revenue $51.2M vs $52.9M in 2024.","Net loss $41.0M ($0.30 per share) vs $44.0M ($0.42) in Q3 2024; adjusted net loss $25.5M ($0.19).","Completed $60M PIPE financing with $57.6M net proceeds; pro forma cash $292.3M to support ZYNLONTA expansion.","LOTIS-7 updated data by end of 2025; LOTIS-5 topline data expected 1H 2026; FL IIT shows ORR 98.2%, CR 83.6%.","IND-enabling for PSMA-targeting ADC to be completed by end of 2025; restructuring costs $13.5M YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":58299000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124763,"accession_number":"0000950103-25-013103","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","2.02","3.02","9.01"],"status":"ready","headline":"ADC Therapeutics raises $60M PIPE; prelim Q3 ZYNLONTA revenue $15.8M, cash $234.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PIPE of 11.25M shares at $4.00 and 3.85M pre-funded warrants at $3.90; gross $60M, close expected Oct 27.","Preliminary Q3 2025 ZYNLONTA net product revenue approximately $15.8M.","Cash and equivalents $234.7M as of Sep 30; pro forma $292.3M after PIPE net proceeds (~$57.6M).","PIPE led by TCGX with Redmile Group and other existing investors; Jefferies acted as placement agent.","Net proceeds to fund ZYNLONTA commercial expansion, strengthen balance sheet, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141454,"accession_number":"0000950103-25-012514","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADC Therapeutics updates with strong LOTIS-7 combo data; ZYNLONTA expansion plans detailed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LOTIS-7 (ZYNLONTA+glofitamab) achieved 86.7% CR rate in r/r LBCL; 93.3% ORR in evaluable patients (N=30).","LOTIS-5 Phase 3 trial fully enrolled; topline data expected 1H 2026 for potential sBLA submission.","ZYNLONTA Phase 2 IIT in r/r MZL showed 69.2% CR and 84.6% ORR (N=26 evaluable); CR maintained in 17/18 patients.","PSMA-targeting ADC progresses IND-enabling activities; seeking research collaborations.","Cash runway expected into 2028; company continues to grow ZYNLONTA revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141453,"accession_number":"0001771910-25-000006","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics Q2 net loss widens to $56.6M; completes $100M PIPE, cuts workforce 30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 product revenue $18.1M (+6% YoY); net loss $56.6M ($0.50/share) vs $36.5M loss ($0.38) in Q2 2024.","Completed $100M PIPE with $93.1M net proceeds; cash $264.6M, expected runway into 2028.","LOTIS-7 (ZYNLONTA+glofitamab) showed 93.3% ORR, 86.7% CR in r/r DLBCL; expansion to 100 patients underway.","Strategic restructuring: discontinuing early solid tumor programs, shutting UK facility, workforce reduction ~30% by Sep 2025.","LOTIS-5 Phase 3 on track to reach PFS events by end of 2025; sBLA filing expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":41872000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159274,"accession_number":"0000950103-25-007282","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.01","2.05","3.02","9.01"],"status":"ready","headline":"ADC Therapeutics announces $100M private placement and restructuring with 30% workforce cut","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$100M private placement: 13.03M shares at $3.53 & 15.73M pre-funded warrants at $3.432; close June 16, 2025.","Board approved restructuring to focus on ZYNLONTA and PSMA ADC; discontinue early preclinical solid tumor programs.","UK R&D facility to shut down; global workforce reduced by ~30%; substantially complete by September 30, 2025.","Estimated one-time pre-tax restructuring charges of $6M-$7M, majority recognized in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159273,"accession_number":"0000950103-25-007061","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ADC Therapeutics elects Timothy Coughlin to board at 2025 AGM; all proposals pass","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Coughlin elected to board; CPA, former Neurocrine CFO, appointed audit committee chair.","Binding votes: board max comp $2.3M, exec fixed $2.6M, variable $3.5M.","Amendment to 2019 Equity Incentive Plan approved to increase authorized shares.","Articles of association amended to raise conditional share capital for employee participation.","All 12 shareholder proposals, including director elections and say-on-pay, approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159272,"accession_number":"0001628280-25-025329","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics Q1 net loss narrows to $38.6M; ZYNLONTA revenue $17.4M, LOTIS-7 shows 95.5% ORR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 product revenue $17.4M vs $17.8M YoY; license revenue $5.6M including $5M Canadian milestone.","Net loss $38.6M ($0.36/sh) vs $46.6M ($0.56); adjusted net loss $24.0M ($0.22).","Cash $194.7M at March 31; runway expected into H2 2026.","LOTIS-7 (ZYNLONTA+glofitamab) enrolled 40 patients; abstract shows 95.5% ORR, 90.9% CR.","LOTIS-5 confirmatory trial on track for PFS events by end of 2025; ADCT-602 discontinued."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":23033000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177704,"accession_number":"0001628280-25-015057","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics reports Q4/FY2024 results: net loss narrows; ZYNLONTA revenue flat; cash runway to H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024 was $30.7M ($0.29/share) vs $85.0M ($1.03) in Q4 2023; full year net loss $157.8M ($1.62) vs $240.1M ($2.94).","ZYNLONTA net product revenue $16.4M in Q4 and $69.3M for FY 2024, roughly flat vs prior year.","Cash $250.9M at Dec 31, 2024; runway into H2 2026 after $97.4M May 2024 offering.","LOTIS-5 Phase 3 confirmatory trial enrollment completed Dec 2024; data update expected late 2025.","LOTIS-7 Phase 1b: 94% best ORR and 72% CR in r/r DLBCL; dose expansion enrollment completing Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177703,"accession_number":"0000950103-25-000411","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ADC Therapeutics releases preliminary 2024 ZYNLONTA sales and expense data at JPM conference","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Preliminary ZYNLONTA net sales and FY2024 expenses disclosed at JPMorgan Healthcare Conference; no specific figures in filing.","Forward-looking statements reference expected cash runway into mid-2026 and potential to grow ZYNLONTA revenue.","Presentation highlights pipeline including LOTIS 5, LOTIS 7, ADCT-602, and exatecan-based solid tumor platform.","ZYNLONTA is approved for relapsed/refractory large B-cell lymphoma after two prior therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":70837000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194424,"accession_number":"0000950103-24-016242","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ADC Therapeutics shareholders approve capital range increase and conditional share capital amendments","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved amendment to Article 4a to increase capital range (52.4M for, 9.0M against).","Shareholders approved amendment to Article 4c to increase conditional share capital for financing/acquisitions (52.3M for, 9.0M against).","Amendments to articles of association became effective immediately upon approval at Nov 11, 2024 special meeting.","Broker non-votes: none reported for either proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194423,"accession_number":"0001628280-24-045995","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics reports Q3 2024 revenue $18.0M; net loss narrows; discontinues ADCT-601","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZYNLONTA net product revenue $18.0M in Q3 2024 vs $14.3M in Q3 2023; year-to-date $52.9M.","Net loss $44.0M ($0.42 per share) in Q3 2024 vs $46.7M ($0.57) in Q3 2023; adjusted net loss $29.4M.","Cash and cash equivalents $274.3M as of Sep 30, 2024; expected runway into mid-2026.","Discontinued ADCT-601 (AXL-targeting) due to unfavorable benefit-risk; prioritizing exatecan-based ADC platform.","LOTIS-5 Phase 3 trial (ZYNLONTA+rituximab) full enrollment expected by year-end 2024; LOTIS-7 data update in Dec 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":53927000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210744,"accession_number":"0001628280-24-034975","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics Q2 2024: ZYNLONTA $17M (−5% QoQ), net loss $36.5M, cash extended to mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZYNLONTA net sales $17.0M in Q2 2024 (−5% QoQ, −11% YoY); commercial profitability achieved.","Net loss $36.5M ($0.38/sh) vs $48.9M ($0.60/sh) in Q2 2023; adjusted net loss $24.4M ($0.25/sh).","Cash $300.1M after $97.4M May 2024 offering; runway extended into mid-2026.","LOTIS-5 Phase 3 IDMC recommended continue; full enrollment expected before year-end 2024.","LOTIS-7 dose expansion on track; safety/efficacy data expected year-end 2024, mature data H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":35463000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229134,"accession_number":"0000950103-24-008385","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"ADC Therapeutics shareholders approve all 12 proposals at 2024 AGM, including director re-elections and compensation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved management report, annual financial statements, and discharge of directors/executive committee for FY2023.","All nine directors reelected; compensation committee members, independent proxy, and PwC auditors also reelected.","Binding approval: board comp cap $2M; fixed exec comp cap $3M (FY2025); variable exec comp cap $10M (FY2024).","Advisory votes: compensation report and say-on-pay passed; shareholders recommended annual frequency, adopted by company.","Articles of association amended in six areas including shareholder rights, meetings, and conditional share capital flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229133,"accession_number":"0000950103-24-006646","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADC Therapeutics posts corporate presentation; no material new disclosures identified","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation dated May 14, 2024 made available for industry conferences and investor meetings.","No specific financial or operational metrics disclosed in the 8-K or exhibit summary.","Presentation contains forward-looking statements; limited detail on pipeline or guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229132,"accession_number":"0000950103-24-006462","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ADC Therapeutics raises ~$105M in public offering of common shares and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 13.4M common shares at $4.90/share and pre-funded warrants for 8.2M shares at $4.812/warrant.","Gross proceeds ~$105M; underwriters include Jefferies, Guggenheim, Cantor Fitzgerald; offering closed May 8, 2024.","Pre-funded warrants exercisable at CHF 0.08/share, with a 9.99% beneficial ownership cap (adjustable to 19.99%).","Warrants have a 10-year term and may be exercised on a cashless basis under certain conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229131,"accession_number":"0001628280-24-020447","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ADC Therapeutics Q1 net loss narrows to $46.6M; ZYNLONTA sales $17.8M; initial MZL data shows 13/15 CR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZYNLONTA net sales $17.8M in Q1 2024, up 7% QoQ, down 6% YoY; total operating expenses down 25%.","Net loss $46.6M ($0.56/share) vs $59.4M ($0.73) in Q1 2023; adjusted net loss $31.1M.","Cash $234.3M as of Mar 31, 2024; cash runway expected into Q4 2025.","LOTIS-5 enrollment on track to complete in 2024; LOTIS-7 dose escalation complete, expansion initiated.","Initial Phase 2 IIT data in r/r MZL: 15 evaluable patients, 13 complete responses (CR) and 1 PR."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":18053000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229130,"accession_number":"0000950103-24-005064","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADC Therapeutics presents exatecan-based ADC platform at virtual investor event","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Ameet Mallik and CSO Patrick van Berkel to present updates on novel exatecan-based ADC platform.","Agenda includes business update, research strategy, platform, and lead candidates.","Presentation made available on April 9, 2024, with live Q&A session to follow.","No financial results or material non-public information disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247734,"accession_number":"0001628280-24-010785","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ADC Therapeutics reports Q4'23 ZYNLONTA sales $16.6M, net loss $85M; cash runway into Q4'25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ZYNLONTA net sales $16.6M in Q4'23 (+17% QoQ, -16% YoY); FY'23 $69.1M (-8% YoY).","Net loss $85M in Q4'23 ($1.03/share) vs $23.3M loss in Q4'22; FY'23 net loss $240.1M ($2.94/share).","Cash $278.6M, expected runway into Q4'25; operating expenses decreased 21% YoY.","LOTIS-5 may need additional patients beyond 350; enrollment still expected to complete in 2024.","ADCT-601 pancreatic cancer screening initiated; LOTIS-7 dose escalation cleared at 150 µg/kg."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247733,"accession_number":"0000950103-24-003406","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ADC Therapeutics presents at Cowen conference; no material updates disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed Form 8-K on March 5, 2024, to disseminate a corporate presentation.","Presentation attached as Exhibit 99.1; no financial or pipeline milestones announced.","Available presentation text contains only forward-looking statements and no new data.","No guidance, revenue, or regulatory changes reported in the filing or exhibit snippet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247732,"accession_number":"0000950103-24-003156","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ADC Therapeutics SA Board approves Annual Bonus Plan for 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan effective retroactively from Jan 1, 2024; bonuses based on corporate objectives approved by Board or Compensation Committee.","Eligible participants: full-time and part-time regular employees in good standing, including named executive officers.","Target bonus expressed as percentage of base salary; payout determined after year-end per payout curve for each objective.","Payment to be made on or before March 15 (US) or end of March (other countries); prorated for new hires, transfers, leaves."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247731,"accession_number":"0000950103-24-001047","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-01-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ADC Therapeutics grants Redmile preemptive rights up to 20% ownership threshold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement preserves Redmile's preemptive and advance subscription rights if group holds ≤20% of share capital.","If group exceeds 20%, board must find no change-of-control intent to keep rights intact; else rights may be restricted.","Redmile caps aggregate voting rights at 15% of share capital unless otherwise mutually agreed.","Agreement terminates upon removal of 20% clauses, 5 years if ownership <20%, redomiciliation, >30% ownership, or change-of-control finding.","Redmile currently owns ~18.93% of shares and has confirmed no present intention to effect a change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247730,"accession_number":"0000950103-24-000925","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ADC Therapeutics amends loan; adds ZYNLONTA sales covenant, eases out-license repay","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New revenue covenant requires ZYNLONTA net sales from $45.5M (trailing 3Q Jun'24) to $94.2M (4Q Jun'29).","Out-licensing repayment threshold raised to $75M (from $50M); mandatory paydown cut to 25% (from 30%).","Covenant not tested if 30-day avg market cap ≥ $650M; prepayment cure right limited to 3 events, max 2 consecutive.","Lenders waived alleged non-financial defaults and consented to potential Delaware reincorporation.","Amendment targets greater flexibility for out-licensing preclinical compounds while adding measurable sales target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247729,"accession_number":"0000950103-24-000237","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ADC Therapeutics regains NYSE minimum bid price compliance; removed from noncompliant list","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Received NYSE notice on Jan 2, 2024 confirming compliance with Section 802.01C.","Cure: closing price on Dec 29, 2023 and 30-trading-day average both above $1.00.","Previously noncompliant due to average closing price below $1.00 over 30 days.","Company will be removed from NYSE's noncompliant issuers list."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247728,"accession_number":"0000950103-24-000236","cik":1771910,"company_name":"ADC Therapeutics SA","ticker":"ADCT","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ADC Therapeutics reports preliminary ZYNLONTA Q4 net sales ~$16.5M; cash ~$278.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary ZYNLONTA Q4 2023 net sales ~$16.5M, double-digit percentage increase from Q3 2023.","Cash and cash equivalents ~$278.5M at Q4-end; cash runway extended to Q4 2025 (prev. mid-2025).","LOTIS-7 combo trial cleared first dosing cohort with no DLT; first 5 evaluable patients all showed response.","ADCT-601 (AXL) reached MTD; early antitumor activity in monotherapy and combination; dose optimization ongoing.","Discontinued ADCT-901 (KAAG1) due to limited efficacy; reallocating capital to prioritized pipeline programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":434815688.8118951,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}